Fundraising Fox
Sapience Therapeutics
Scarsdale, US · Founded 2015 · Delaware corporation · 23 employees on LinkedIn · 5 known investors
Find your way into Sapience Therapeutics
Sign up to see every warm intro you have to Sapience Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sapience Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Sapience Therapeutics is a clinical-stage biotechnology company developing peptide-based cancer therapies that target traditionally undruggable oncogenic proteins and protein-protein interactions. Its pipeline includes SPEAR peptides that act inside cancer cells and SPARC peptides that act on the outside, with lead candidates lucicebtide (ST101) and ST316 in Phase 2 oncology trials.
Founders & leadership
Sapience Therapeutics was founded in 2015 by Barry Kappel, Ph.D..
Board
Investors · 5
Also in the syndicate · 3
Funding
SEC filings, press & company announcements$49.3M disclosed across 3 of 5 rounds · 2015–2022
- $41MSeries BJun 2022 · 2 sources
NexPoint (lead), Bristol Myers Squibb, Eshelman Ventures, Kingdon Capital
Source ↗ - Undisclosed amountSeries BMay 2022
NexPoint (lead), Bristol Myers Squibb, Eshelman Ventures, Kingdon Capital
Source ↗
▶$8MraisedJul 2020 · 83 investors · BiotechnologyRule 506(b)
- Christian SchadeDirector
- Barry KappelExecutive Officer, Director
- David ScheinbergDirector
- Howard PienDirector
- Robert RuffoloDirector
- Offering amount
- $30M
- Amount sold
- $8M
- Minimum investment
- $50K
- Sales commissions
- $701.1K
- Placement agents
- Maxim Group LLC
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$22.5MofferedApr 2016 · BiotechnologyRule 506(b)
- Robert Ruffolo, Ph.D.Director
- Barry Kappel, Ph.D.Executive Officer, Director
- David Scheinberg, Ph.D.Director
- Howard PienDirector
- Isaac BlechDirector
- Offering amount
- $22.5M
- Minimum investment
- $50K
- Sales commissions
- $800K
- Placement agents
- Maxim Group LLC
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$300KraisedJan 2016 · 3 investors · BiotechnologyRule 506(b)
- Robert Ruffolo, Ph.D.Director
- David Scheinberg, Ph.D.Director
- Isaac BlechDirector
- Barry Kappel, Ph.D.Executive Officer, Director
- Offering amount
- $1M
- Amount sold
- $300K
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Sapience Therapeutics.
In the news
Frequently asked questions
- What does Sapience Therapeutics do?
- Sapience Therapeutics is a clinical-stage biotechnology company developing peptide-based cancer therapies that target traditionally undruggable oncogenic proteins and protein-protein interactions. Its pipeline includes SPEAR peptides that act inside cancer cells and SPARC peptides that act on the outside, with lead candidates lucicebtide (ST101) and ST316 in Phase 2 oncology trials.
- Who founded Sapience Therapeutics?
- Sapience Therapeutics was founded by Barry Kappel, Ph.D. in 2015.
- Who are Sapience Therapeutics's investors?
- Sapience Therapeutics's investors include Connectivity Ventures, Eshelman Ventures, LLC.
- How much funding has Sapience Therapeutics raised?
- Sapience Therapeutics has disclosed $49.3M raised across 3 of its 5 known rounds.
- Where is Sapience Therapeutics headquartered?
- Sapience Therapeutics is headquartered in Scarsdale, US.